Today, PDX Pharmaceuticals was awarded a phase II SBIR contract from National Cancer Institute for $1.0 million for the performance period of June, 2014-2016. The contract covers the development of siRNA-nanoparticle platform for HER2 positive breast cancer therapy. This award follows the success of Phase I contract of $200,000 from NCI to PDX Pharmaceuticals from September 2013-June 2014.